Clinical Efficacy definition

Clinical Efficacy means [*].
Clinical Efficacy means the following with respect to each of EPO, HEPATITIS B AND IL-2:
Clinical Efficacy means the following with respect to each of EPO, HEPATITIS B AND IL-2: PRODUCT CLINICAL EFFICACY ----------------- ----------------------------- EPO A statistically significant increase in hematocrit in patients with anemia secondary to compromised renal function, including patients on dialysis. -3- HEPATITIS B Seroconversion (anti HBs Ag- to + in normal adults) in incidence and titer comparable to existing Hepatitis B vaccine.

Examples of Clinical Efficacy in a sentence

  • Following the demonstration of Clinical Efficacy or earlier as determined by the JSC, the Parties will arrange for end-of-phase 2 meetings (as described in 21 CFR 312.47(b) or equivalent foreign regulations) with each of the FDA and EMA (each, an “EOP2 Meeting”).

  • In consideration for the grant of the Option and the provision by AVEO of the AVEO Materials, Ophthotech shall pay AVEO a one-time milestone payment of six million Dollars ($6,000,000) within [**] days after the Clinical Efficacy Milestone Payment Trigger Date.

  • The Study shall be conducted in full compliance with the Sponsor's protocol VTX002-201 “A Phase 2, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects with Moderately to Severely Active Ulcerative Colitis” and any amendments thereto (the “Protocol”).

  • Ophthotech may exercise the Option at any time until the latest to occur of: (i) twelve (12) months after the achievement of the Clinical Efficacy Milestone, (ii) ninety (90) days after the Clinical Efficacy Milestone Payment Trigger Date, and (iii) thirty (30) days after AVEO and Ophthotech agree as to the definitive form of license agreement (the “Option Period”).

  • Ophthotech shall also notify AVEO of the achievement of the Clinical Efficacy Milestone within such [**] days after such achievement.

  • Prior to the full payment of the amounts required under Section 2.3, IDEC shall provide Pharmacia biannual progress reports of the development of 9-AC, including summary reports of the clinical studies conducted by NCI under the CRADA and information sufficient to indicate the extent of progress, if any, toward demonstration of Clinical Efficacy and submission and approval of the NDA for 9-AC.

  • Notwithstanding the foregoing, such payment shall not be payable if Ophthotech gives AVEO a notice of termination pursuant to Section 9.5 on or prior to the date [**] days after the Clinical Efficacy Milestone Payment Trigger Date, whether or not such termination becomes effective prior to the date [**] days after the Clinical Efficacy Milestone Payment Trigger Date.

  • IDEC shall promptly notify Pharmacia upon the occurrence of Clinical Efficacy.

  • The Parties will endeavor to conclude its negotiations no later than the later of [**] days after AVEO enters into the KHK Agreement Amendment with KHK or [**] days after the Clinical Efficacy Milestone.

  • If, at the time Ophthotech exercises the Option, the Clinical Efficacy Milestone Payment Trigger Date has not yet occurred, Ophthotech shall pay the milestone set forth in Section 4.3 after such Option exercise at such time as the Clinical Efficacy Milestone Payment Trigger Date does occur if the License Agreement remains in effect as of such subsequent occurrence.


More Definitions of Clinical Efficacy

Clinical Efficacy means *____________*. The "Registration Trial" shall mean *_______________*. Promptly after its agreement with the FDA, IDEC shall submit to P&U SPA a copy of *____________*. If a *___________* with the FDA, the parties shall agree upon reasonable alternative criteria to demonstrate clinical efficacy in any tumor type. IDEC shall promptly notify Pharmacia upon the occurrence of Clinical Efficacy. If Pharmacia has reasonable reason to believe that Clinical *Indicates that material has been omitted and confidential treatment has been requested therefor. All such omitted material has been filed separately with the Secretary of the Commission in the Company's Application Requesting Confidential Treatment pursuant to Rule 246-2 under the Securities Exchange Act of 1934, as amended.